ENDRA Life Sciences Inc.
NDRA • NASDAQ
ENDRA Life Sciences Inc. is a medical - diagnostics & research company in the healthcare sector trading on NASDAQ, led by CEO Alexander Y. Tokman, with a market cap of $4.4M.
CEOAlexander Y. Tokman
Market Cap$4.4M
Medical - Diagnostics & Research
Healthcare
Employees21.0
Websiteendrainc.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for ENDRA Life Sciences Inc.
Date
Monday, March 30, 2026 (in 2 months)
Timing
Before Market Open (8:00 AM New York)
Fiscal Period
Q4 2025
EPS Estimate
-$1.23
Earnings History
Past 12 earnings reports for ENDRA Life Sciences Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Nov 17, 2025 | Q3 2025 | -$2.10Est: -$1.95 | -7.7% | - | — |  10-Q |
| Aug 14, 2025 | Q2 2025 | -$1.71Est: -$2.27 | +24.7% | - | — | 10-Q |
| May 15, 2025 | Q1 2025 | -$1.86Est: -$142.80 | +98.7% | - | — | 10-Q |
| Mar 31, 2025 | Q4 2024 | -$7.35 | — | - | — | 10-K/A |
| Nov 15, 2024 | Q3 2024 | -$333.90Est: -$70.00 | -377.0% | - | — | 10-Q/A |
| Aug 14, 2024 | Q2 2024 | -$140.00Est: -$122.50 | -14.3% | - | — | 10-Q |
| May 14, 2024 | Q1 2024 | -$455.00Est: -$472.50 | +3.7% | - | — | 10-Q |
| Mar 28, 2024 | Q4 2023 | -$297.50Est: -$630.00 | +52.8% | - | — | 10-K |
| Nov 14, 2023 | Q3 2023 | -$700.00Est: -$752.50 | +7.0% | - | — | — |
| Aug 14, 2023 | Q2 2023 | -$752.50Est: -$962.50 | +21.8% | - | — | — |
| May 15, 2023 | Q1 2023 | -$1,627.50Est: -$1,820.00 | +10.6% | - | — | — |
| Mar 14, 2023 | Q4 2022 | -$1,680.00Est: -$1,575.00 | -6.7% | - | — | — |